WILEY (JOHN) + SONS B

Wiley reported Q1 FY2027 EPS of 0.44 USD and revenue of 386 million USD, slightly below consensus. The stock rose premarket after the company confirmed its full-year outlook (adjusted EPS 4.60–5.05 USD, free cash flow 205 million USD), improved cash flow and signaled further growth in research and AI. The research segment grew 4% (scientific publishing +12%), while the learning segment shrank 20%; AI revenues were 14 million USD in the quarter with a further 14 million USD contractually committed. Management cites successful integration at Emerald, high submission volumes and increasing demand for data and AI products as reasons for confidence, but points to risks such as continued weakness in the learning business and higher leverage. » More on de.investing.com

Wiley has launched an API portfolio that provides direct access to its spectral databases and analysis tools within laboratory workflows. The four APIs offer spectral-database search, validation of spectrum–structure relationships, compound classification and spectrum prediction. Target customers are labs, instrument manufacturers and software platforms; the integration is intended to support automated queries, regulatory compliance and cross-platform interoperability. The databases cover techniques such as IR, MS, NMR and Raman and are used, among others, in pharma, forensics, environmental and materials science. » More on de.investing.com

The shares of John Wiley & Sons rose to a new 52‑week high of $53.28, representing a year-to-date gain of 33.4%. For the fourth quarter of fiscal 2026 the company reported adjusted earnings per share of $1.67, beating expectations, while revenue of $447.9 million was slightly below forecasts. InvestingPro continues to rate the stock as undervalued and highlights Wiley’s long record of dividend increases. The board approved a quarterly cash dividend of $0.3575, raising the annual dividend to $1.43. » More on de.investing.com